US4021555A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical preparation and method for treatment of parkinsonism
Assignee: Merck Patent GmbH
•
Filing: 1975-12-16
•
Granted: 1977-05-03
•
Expires: 1995-12-16
Abstract
Abstract Administration of mepiprazole during L-dopa therapy for parkinsonism reduces undesired side effects of L-dopa and enhances the desired effects of L-dopa.
Inventors
- 👤 Christoph Seyfried
- 👤 Herbert Nowak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 20:24
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
50 words
A pharmaceutical composition comprising in unit dosage form an amount of L-dopa effective to alleviate the symptoms of parkinsonism and a dosage of mepiprazole or a pharmacologically acceptable acid addition salt thereof, effective to reduce undesired side effects of the amount of L-dopa, in admixture with a pharmacologically acceptable carrier.
Claim 2
Dependent Claim
50 words
A pharmaceutical composition comprising in unit dosage form an amount of L-dopa effective to alleviate the symptoms of parkinsonism and a dosage of mepiprazole or a pharmacologically acceptable acid addition salt thereof, effective to reduce undesired side effects of the amount of L-dopa, in admixture with a pharmacologically acceptable carrier.
Claim 3
Dependent Claim
24 words
The composition of claim 1, wherein the amount per unit dosage of mepiprazole is 0.1 - 2% by weight of L-dopa per unit dosage.
Claim 4
Dependent Claim
19 words
The composition of claim 1, wherein the amount of mepiprazole per unit dosage is from 0.5 to 20 mg.
Claim 5
Independent Claim
72 words
A method for enhancing the beneficial effects, for reducing the undesirable effects, or for both enhancing the beneficial effects and reducing the undesirable effects of therapy with L-dopa in the treatment of parkinsonism comprising administering during said therapy an amount of mepiprazole or a pharmacologically acceptable salt thereof, effective to enhance said beneficial effects, to reduce said side effects, or to both enhance said beneficial effects and to reduce said side effects.
Claim 6
Independent Claim
72 words
A method for enhancing the beneficial effects, for reducing the undesirable effects, or for both enhancing the beneficial effects and reducing the undesirable effects of therapy with L-dopa in the treatment of parkinsonism comprising administering during said therapy an amount of mepiprazole or a pharmacologically acceptable salt thereof, effective to enhance said beneficial effects, to reduce said side effects, or to both enhance said beneficial effects and to reduce said side effects.
Claim 7
Dependent Claim
19 words
The method of claim 4, wherein the mepiprazole and L-dopa are administered as a mixture in unit dosage form.
Claim 8
Dependent Claim
12 words
The method of claim 4, wherein L-dopa and mepiprazole are administered orally.
Claim 9
Dependent Claim
34 words
The method of claim 4, wherein the daily dosage of L-dopa is from 500 to 6000 mg. and the daily dosage of mepiprazole is 0.1 - 2% by weight of said dosage of L-dopa.
Claim 10
Dependent Claim
22 words
The method of claim 7, wherein said unit daily dosages of L-dopa and mepiprazole are given in up to 10 fractional dosages.
References Cited (Backward Citations)
US3632778A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-05-02 | 1980-11-01 | 1981-05-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-05-02 | 1984-11-01 | 1985-05-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-05-02 | 1988-11-01 | 1989-05-03 | $7700.00 | Window Closed / Lapsed |